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Atrial fibrillation (AF) and arterial stiffness (AS) greatly increase with age. In elderly
patients, AF is often a marker of frailty and is frequently associated with important
diseases and complications, such as stroke, heart failure, dementia, chronic obstruc-
tive pulmonary disease, pneumonia, acute myocardial infarction and urinary infec-
tions. Little is known about the influence of vascular properties on AF. In a first ex-
periment, to verify the existence of a possible association between arrhythmia and
vascular properties, we evaluated the Cardio-Ankle Vascular Index (CAVI), a measure
of AS, in 33 patients (age: 736 12 years) at 5 h from effective external cardioversion
(ECV) of persistent AF. We found that CAVI was a direct independent predictor of left
atrial diameter. This association did not exist in a healthy control population
(N¼ 18). In a second experiment, conducted in 31 patients (age: 786 7 years), we
studied the possible association between AS and AF after ECV of the arrhythmia. At
follow-up (on average at 6 months), we observed the arrhythmia in 48% of cases and
found that its presence was directly related to CAVI values and CHA2DS2-VASc score.
Introduction
Atrial fibrillation (AF) is the most common sustained ar-
rhythmia in elderly people.1 The prevalence of AF greatly
increases after 60 years of age, being higher than 20% in
subjects85 years.2 In a population of ‘oldest old’ subjects
evaluated by general practitioners in a large British com-
munity, the prevalence of the arrhythmia was similar to
that observed for chronic obstructive pulmonary disease,
heart failure (HF), and osteoporosis.3 This relevant epide-
miological trend is due to the aging process of the cardio-
vascular system and to the increase of comorbidities. In
fact, in elderly patients, AF is often associated with HF,
pneumonia, acute myocardial infarction and urinary infec-
tions,4 and it can be considered a marker of frailty.5 AF can
also determine severe complications, such as stroke6 and
dementia.7 Interestingly, epidemiological data show that
old patients with AF have a median of six different diagno-
ses, among which hypertension, coronary artery disease,
hyperlipidemia, diabetes mellitus, and chronic renal fail-
ure have a significant association with atherosclerosis.8
Pulse wave velocity, a measure of arterial stiffness (AS),
starts to increase after 50 years of age following a cubic
trend.9 Contrasting evidence exists about the interaction
between vascular properties and AF development and
maintenance. During a follow-up lasting 12 years, the
Framingham Heart Study demonstrated that the incidence
of AF progressively grew from 5.6 to 23.3% mirroring the in-
crease of basal pulse pressure from40 to>61mmHg.10
Also in the hypertensive patients enrolled in the LIFE (the
Losartan Intervention For Endpoint reduction in hyperten-
sion) study, new cases of arrhythmia were more frequently
observed in those with higher pulse pressure values.11 In
the ARAPACIS (the Atrial Fibrillation Registry for Ankle-
Brachial Index Prevalence Assessment Collaborative Italian
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Study) study the prevalence of subjects with ankle-
brachial index (ABI) values<0.90 increased from 18 to 24%
with the progressive growth of arrhythmia burden (i.e.
from paroxysmal to permanent forms of AF).12 However,
more recently, the parallel analysis of data from the ARIC
(Atherosclerosis Risk in Communities), the MESA (Multi-
Ethnic Study of Atherosclerosis) and the Rotterdam studies
revealed that carotid intima-media thickness and AS pre-
dict AF development, albeit with only a modest statistical
power.13
On this basis, we conducted two consecutive stud-
ies.14,15 The first was aimed at determining the clinical fac-
tors correlated to AS in a population of patients who
underwent external cardioversion (ECV) of the persistent
forms of the arrhythmia. Then, we verified if an association
exists between AS, left atrial and left ventricular dimen-
sions. The existence of this link could justify the incidence
of relapses after sinus rhythm restoration.14 With the sec-
ond study, we aimed at evaluating in a new population of
aged patients if AS can be related to sinus rhythm mainte-
nance after ECV.15 For this purpose, we took into consider-
ation also interleukin-6 (IL-6) concentration, which
revealed itself to be associated with both AS and AF
relapses.15,16
Methods
We enrolled all consecutive patients who underwent ECVof
persistent AF between January and June 2013 in the first
study, and between March and December 2015 in the sec-
ond study. The procedure was electively performed in the
morning, in a day-hospital setting according to current
guidelines.6 In particular, after at least 3 weeks of oral anti-
coagulation, all patients in fasting conditions received i.v.
propofol at a dose of about 1mg/Kg of body weight to in-
duce general anesthesia. To restore sinus rhythm, a
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synchronized biphasic shock was de-
livered through adhesive pads placed in antero-posterior or
antero-lateral position with progressively increasing ener-
gies in case of failure of the preceding attempt (starting
value: 150 J).17 ECV was interrupted after three consecu-
tive ineffective shocks. In this case, based on individual
clinical conditions, a decision was taken about scheduling a
new procedure after adjustment of anti-arrhythmic treat-
ment or pursuing a rate-control strategy.6
A trans-thoracic echocardiogram using MyLabTM30Gold
Cardiovascular (ESAOTE SpA, Florence, Italy) was obtained
and digitally recorded after sinus rhythm restoration in all
patients immediately before the discharge from the day-
hospital, at 5 h from ECV. At the same time, the ‘cardio-an-
kle vascular stiffness index’ (CAVI), an index of AS, inde-
pendent of actual arterial blood pressure values, was
determined using a dedicated device (VaSera VS-1500N,
Fukuda Denshi, Japan).18 Patients had to be lying down for
at least 20min before CAVI wasmeasured.
During the continuous recording of EKG and heart
sounds, right and left upper and lower extremity arterial
pressure was obtained with the oscillometric method.
Pulse wave velocity (PWV) was calculated dividing the dis-
tance from the aortic valve to the ankle by the sum of two
time intervals [(1) aortic valve closing sound–notch of the
brachial pulse wave; (2) rise of the brachial pulse wave–rise
of the ankle pulse wave]. CAVI was then computed using
the following equation:
CAVI ¼ a ½ð2q=DPÞ  lnðPs=PdÞ  PWV2 þ b
where Ps/Pd are systolic/diastolic pressures, DP is ‘Ps–Pd’,
q is blood density, and a/b are constants.18
We decided to evaluate CAVI after ECV to avoid any pos-
sible bias associated to irregular RR intervals. The complex
mechanisms of atrial reverse remodelling should have not
significantly changed left atrium properties after such a
short period from sinus rhythm restoration. No exclusion
criteria were defined.
At baseline, before ECV, a venous blood sample was
drawn in 27 out of 31 (87.1%) patients enrolled in the sec-
ond study to determine IL-6 concentration with commer-
cially available ELISA kits (R&D Systems, Inc.; Minneapolis,
MN, USA).
At the follow-up (mean length: 179 days, 33th-66th per-
centile: 104–252 days) evaluation, we had no dropouts; ar-
terial blood pressure, EKG and main clinical events were
recorded for all subjects.
In addition, to verify the existence of a specific
arrhythmia-related behaviour, echocardiographic, and
CAVI data of a healthy control population–patients from our
outpatient clinic–were compared with those with AF en-
rolled in the first study.
Statistical analysis
Continuous variables are expressed asmean values (6 stan-
dard deviation) and categorical variables as raw data and
percentages. Student’s t-test and analysis of variance,
with related non-parametric tests in the case of a not
normal distribution, were used to verify the existence of
differences in continuous variables between groups of
patients. Chi-square test and associated tests assessed
the differences in distribution of discrete variables.
Multivariate linear regression analysis models andmultivar-
iate logistic regression analysis models were used to define
the predictors of CAVI and AF relapses, respectively. Two-
tailed P values<0.05 were considered to indicate statisti-
cal significance. For all the analyses, we used SPSS for
Windows, version 22 and 23.
Results
First study population
In the first study, aimed at exploring the relationship be-
tween AF and AS,14 we enrolled 33 patients. Mean age was
736 12 years; 85% were men, body mass index (BMI) was
27.06 5.0Kg/m2. Prevalence of hypertension, coronary ar-
tery disease and HF were 67, 18, and 33%, respectively.
The most frequently observed valvular disease was mitral
regurgitation (51%). Diabetic subjects were 12% of the
whole population. Upstream therapy of AF was widely
adopted (ACE-I/ARB: 82%; beta-blockers: 76%). The values
of systolic/diastolic arterial pressure were 1406 16/
856 11mmHg. Left atrial diameter (LAD), interventricular
septum, and left ventricular end-diastolic diameter (LVDD)
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were 506 7mm, 106 1mm, and 566 9mm, respectively;
left ventricular ejection fraction (LVEF) was 566 14%. The
ABI values were normal, with no differences between right
and left side measures (right: 1.106 0.15 vs. left:
1.076 0.12, P¼ 0.222). Also CAVI did not differ by side of
evaluation (right: 9.66 1.6 vs. left: 9.66 1.6, P¼ 0.777).
CAVI predictors in AF patients
When carrying out univariate analysis, CAVI was signifi-
cantly associated with age (P¼ 0.025), BMI (b¼ –0.16 0.1,
P¼ 0.037), AF length3 months (yes: 10.16 1.5 vs. no:
8.96 1.5, P¼ 0.031), and mitral regurgitation (yes:
10.36 1.4 vs. no: 8.96 1.6, P¼ 0.012). The presence of di-
abetes, hypertension, coronary artery disease and HF did
not correlate at all with AS; CAVI values did not differ by AF
causes (P¼ 0.657). Moreover, AS was not associated with
interventricular septum thickness, LVDD, and LVEF.
However, a direct correlation existed between CAVI and
LAD (P¼ 0.011) (Figure 1). In multivariate analysis (overall
R¼ 0.538, P¼ 0.006), age, with a 0.5 index increase every
10 years of age (b¼ 0.56 0.2, P¼ 0.018), and an AF
length3 months (b¼ 1.26 0.5, P¼ 0.018) predicted
CAVI.
LAD predictors in AF patients
In our series of patients, apart from CAVI, LAD was directly
correlated only with interventricular septum thickness
(P¼ 0.030). No association existed with age, gender, BMI,
comorbid conditions, and drug therapy. A multivariate
model (R¼ 0.574, P¼ 0.002) confirmed that both CAVI
(b¼ 1.96 0.7, P¼ 0.007) and interventricular septum
thickness (b¼ 1.86 0.7, P¼ 0.018) were determinants of
LAD.
Control patients
Our control population was represented by 18 subjects
younger than AF patients (516 14 years; men: 37%; both P-
values<0.001 vs. AF population). CAVI was significantly
lower than that observed in arrhythmic patients (7.76 1.2,
P< 0.001). Also in this case, a direct association existed
between age and AS (b¼ 0.66 0.1 per 10 years of age,
P< 0.001). Importantly, no correlation existed between
CAVI and LAD (Figure 1).
Second study population
In the second study, we assessed the effects of AS on AF re-
lapse after ECV,15 enrolling 31 patients (mean age: 786 7
years), of which 67.7% were men. The prevalence of hyper-
tension was high (87%), with a proportion of coronary ar-
tery disease, chronic heart failure and diabetes (29.1,
48.4, and 25.8%, respectively) greater than that observed
in the previous study. CHA2DS2-VASc score (mean:
4.16 1.6) and CAVI were high (mean: 9.96 1.6). Left ven-
tricular systolic performance was preserved (LVEF:
616 9%) and LAD higher than normal (mean: 526 4mm).
Also in this case, upstream therapy was widely adopted
(ACE-I/ARB: 87%; beta-blockers: 71%). Amiodarone was the
most frequently prescribed anti-arrhythmic agent (45%). In
48% of cases, AF had a length2months.
Efficacy of ECV and clinical predictors of AF at
follow-up
ECV restored sinus rhythm in 28 patients (90%). At follow-
up AFwas observed in 48% of cases.
In univariate analysis, patients with AF were older
(816 4 vs. 746 8, P¼ 0.005), with a higher prevalence of
diabetes (47 vs. 6%, P¼ 0.015), higher baseline systolic ar-
terial pressure (1416 20 vs. 1276 20, P¼ 0.036) and
greater CHA2DS2-VASc score (5.06 1.4 vs. 3.36 1.4,
P¼ 0.003). Also AS, as measured by CAVI, was significantly
increased (Figure 2). The prevalence of an AF length2
months was more frequently found in those with arrhyth-
mia (80 vs. 25%, P¼ 0.004). Interestingly, at least in the
medium term, amiodarone exerted a protective role on AF
relapse (Amiodarone use–AF: 20% vs. sinus rhythm: 69%,
P¼ 0.011). Increasing IL-6 concentrations corresponded to
increasing values of CAVI (Figure 2) and CHA2DS2-VASc
score, and to higher proportions of patients with AF at
follow-up (Figure 3).
A multivariate logistic regression analysis model (overall
predictivity: 83.7%) showed that, at follow-up, AF was
directly associated to CHA2DS2-VASc score (OR per 1 point
difference¼2.65, 95%CI¼ 1.01–6.94; P¼ 0.048) and to CAVI
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Figure 1 Correlation between ‘cardio-ankle vascular stiffness index’ (CAVI) and left atrial end-systolic diameter in atrial fibrillation patients (left) and
in a control population (right).
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(OR per 1 unit difference¼2.31, 95%CI¼ 1.01–5.25; P¼ 0.046).
Amiodarone use was found to be inversely related to AF re-
lapse (OR Yes vs. No¼0.05, 95%CI¼ 0.01–0.70; P¼ 0.027).
Discussion
AS, evaluated with CAVI, is directly associated with age
also in cases of persistent AF. Interestingly, in our patients,
CAVI, together with interventricular septum thickness, is
an independent predictor of left atrial dimensions. This
correlation was not found in a population of control
subjects.
As previously mentioned, in a large cohort of patients
with non valvular AF, the prevalence of vascular disease,
condition assigned for ABI values0.90, was high and equal
to 21%.12 Our experience extends this result, demonstrat-
ing that AS can exert a significant influence on LAD. A possi-
ble explanation of this link could be the synergy between
left atrium and left ventricle, with the degree of atrial dila-
tion expressing the severity of ventricular diastolic dys-
function.19 However, in our multivariate model, CAVI
remained an independent predictor of LAD even after ad-
justment for interventricular septum thickness, an expres-
sion of impaired ventricular relaxation.20 The presence of
mitral regurgitation could represent a possible explanation
of the association between AS and atrial dimensions.
Recently, it was found that the loss of arterial distensibility
could stimulate inflammation and vascular smooth muscle
cell contraction in atrial tissues.21 More in detail, it was ob-
served that several comorbid conditions could induce an
inflammatory-mediated coronary micro-vascular dysfunc-
tion, able to accelerate the processes leading to myocar-
dial stiffness development.22 In particular, the endothelial
induced production of Transforming Growth Factor–b, with
the consequent fibroblast-dependent collagen release,
and the increased hypertrophy and resting tension of cardi-
omyocytes, secondary to the reduced activity of protein ki-
nase G, could play a significant part in the process linking
AS, left ventricular diastolic dysfunction and left atrial di-
mensions.22 A key-role in the promotion of this cascade of
events could be exerted by several mediators, among
which one of the most important is IL-6.22 In this regard,
the close link between AF burden and the degree of sys-
temic inflammation is well known.23 Furthermore, in the
series of patients enrolled in our second study we showed
the existence of a linear relationship between IL-6 concen-
trations and the CHA2DS2-VASc score and, importantly, the
proportion of AF at follow-up. These considerations help to
explain the direct relationship between AS and the pres-
ence of arrhythmia at follow-up, which is arguably our
most interesting result. For each one-unit increase of CAVI,
our measure of AS, the risk of finding AF at the control visit
was 2.31 times higher. These results are the first to demon-
strate that in an elderly population undergoing ECV the
presence of AF at follow-up is directly related to vascular
properties. In our patients, the CHA2DS2-VASc score itself
proved a multivariate predictor of the presence of arrhyth-
mia after ECV. As in previous experiments, the score was
significantly associated with early and late recurrences of
AF,24,25 revealing itself as a useful tool to identify those pa-
tients with a global, higher, risk of events. Indeed, in el-
derly subjects, during a 2-year follow-up, scoring 9, when
compared to 0, was associated with a three times greater
probability to be admitted into hospital for cardiovascular
causes.26
Study limitations
Our experience originated in a single centre and it was con-
ducted in two small series of patients. Moreover, it was pos-
sible to measure IL-6 concentration in only 27 of the 31
subjects (87.1%) enrolled in the second study. However, our
results seem to be biologically and clinically consistent,
and they could represent a basis for further, larger,
experiences.
Conclusions
Through CAVI, an index of AS, easily measured at the bed-
side, we showed the existence of a physio-pathological link
between AS, atrial dimensions and arrhythmia relapse in
patients with persistent AF. As already mentioned, patients
were assessed only a few hours after sinus rhythm resto-
ration, a time interval too short to overcome the alter-
ations that characterize the atrial remodelling process.27
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Figure 2 Cardio-ankle vascular stiffness index (CAVI) in patients with
and without atrial fibrillation at follow-up (left) and by Interleukin-6 (IL-
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Figure 3 CHA2DS2-VASc score (left) and proportion of patients with
atrial fibrillation (AF) at follow-up (right) by Interleukin-6 (IL-6) concen-
tration. In both cases, a direct relation is evident.
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Interestingly, this correlation between vascular properties
and LAD was not found in a control population and it is pos-
sibly mediated by both mechanical and circulating factors.
Our findings emphasize the importance of the ‘atrial-ven-
tricular-arterial association’ in promoting the development
and the maintenance of the arrhythmia and its frequent re-
lapses. If these data are confirmed, AS evaluation will be-
come a key component in the medical assessment of older,
comorbid, AF patients.
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